Overview

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients with drug-sensitive pulmonary tuberculosis.
Phase:
Phase 2
Details
Lead Sponsor:
Sequella, Inc.
Treatments:
Oxazolidinones